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as a result of regulating tumor cell dif-
ferentiation. It is possible that regula-
tion of calcium cellular influx may
modulate mitogenic signal transduction
pathways in SCLC tumors, potentially
inhibiting tumor cell proliferation.5
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Differences of Gene
Expression in Non-
small Cell Lung Cancer
Are Histology, Tumor
Site, and Methodology
Relevant?
To the Editor:
A number of studies have been
carried out to identify predictive bi-
omarkers of chemotherapy activity in
non-small cell lung cancer (NSCLC).
Unfortunately, the results obtained are
contradictory, and tailored treatment of
patients on the basis of gene expression
profiles is still far from being standard-
ized. A possible explanation could re-
side in differences of gene or protein
expression depending on tumor histol-
ogy or site of biopsy. Because only few
studies have tried to address this critical
point, we appreciated the article by
Kang et al.1 By means of immunohisto-
chemistry (IHC), they observed that the
expression of ERCC1 and XRCC1 was
similar in adenocarcinoma and squa-
mous cell carcinoma.
Accordingly, in our study,2 look-
ing at the expression level of genes
involved in gemcitabine and cisplatin
activity, with quantitative real time
(RT)-polymerase chain reaction (PCR)
analysis, we found that ERCC1 ex-
pression is not influenced by NSCLC
histology, suggesting that adenocarci-
noma and squamous cell carcinoma
have a similar genetic susceptibility to
platinum compounds. Indeed, a recent
clinical study3 showed that the out-
come after cisplatin-gemcitabine treat-
ment is similar in patients affected by
adenocarcinoma or squamous cell his-
tology tumors. Kang et al. also re-
ported that ERCC1 and XRCC1 were
overexpressed in neoplastic lymph
nodes compared with primary tumors.
On the contrary, we did not observe
any significant difference in expres-
sion with respect to the origin of the
specimens. The possible reasons for
data discrepancy could be due to not
only the different ethnicity of the pa-
tients (Asian versus Caucasian) but
also the different methods and targets.
Although the study included three
different proteins investigated in a rela-
tively small sample size, the authors did
not perform correction for multiple vari-
ables in their statistical method. Another
important point is the different technique;
in the work by Kang et al., protein expres-
sion was evaluated by IHC in paraffin-
embedded specimens, whereas we mea-
sured mRNA expression by quantitative
RT-PCR in laser-microdissected frozen
tumors. IHC is a sensitive and versatile
method, but it is largely empirical; the
outcome depends on the antibody used
and on the expertise of the pathologists. In
the specific case, there is not yet a consen-
sus about the antibody 8F1, which was
used by Kang et al.1 to detect the ERCC1
protein.4
Quantitative RT-PCR method is
a sensitive and specific technique, with
appropriate controls that can be used
for intralaboratory or interlaboratory
validation. We are aware that mRNA
can differ from protein expression, and
we believe that optimization of both
these methodologies and standardiza-
tion of technical procedures are neces-
sary before larger retrospective and
prospective studies can address the
same pharmacogenetic question. Other
critical points of the study regard the
heterogeneity of treatments and the
different stage and lymph node infil-
tration. All these factors could be con-
founding elements in the analysis of
correlation with outcome.
In conclusion, we agree with
Kang et al.1 that retrospective obser-
vational studies on histology and tu-
mor site can provide strong rationale
for future trials, but we believe that
optimization or standardization of
technical procedures and the use of
larger and uniformly treated popula-
tions are crucial before prospective
studies can identify the best markers
for tailored treatment of NSCLC pa-
tients.
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In Response:
We thank Dr. Toffalorio and co-
workers for their comments and interest in
our article. All their questions were valu-
able, and they reminded us of the potential
problems of our study. As Dr. Toffalorio
commented, standardization and optimi-
zation are big issues in immunohisto-
chemistry (IHC). This is one of the major
obstacles preventing generalization of
IHC data. To maintain the quality of tests
and standardization, we performed several
pilot tests with different antibody con-
centrations in normal lung tissue and
other cancer tissues. After this, we
chose the optimal concentration level,
and this was used in this study. To
minimize the technical error, we made
a tissue array and most of the proce-
dures were performed by an automated
method and not by the manual method.
We initially tried to include a needle
aspiration biopsy specimen, yet it was
difficult to mount the small amount of
tissue on the tissue array, so IHC was
performed by the manual method;
however, the quality of IHC staining
was unstable. So, we discarded the
data drawn from the manual method. It
is our opinion that the method used in
this study was quite reliable and repro-
ducible.
Dr. Toffalorio and coworkers
also questioned about clone 8F1 antibody.
However, another research group in our in-
stitute and other researchers have already
reported studies that were performed us-
ing the same antibody clone.1–3 We think
that this antibody is one of the reliable
antibodies that can be used for IHC of
ERCC1.
In terms of the correction of mul-
tiple variables, we did not perform mul-
tivariate analysis. Because we did not
have a large number of cases in each
stage, we thought it would be impracti-
cal to conduct multivariate analysis on
such a small number of cases. Further-
more, the most important point that
should be addressed was not the differ-
ence in survival but the difference of
protein expression between the primary
tumors and the metastatic lymph nodes,
so we thought that multiple comparison
correction was not a critical prerequisite
for this study. However, we have a plan
to include the results of multivariate
analysis in a future study with a larger
number of cases.
We had 30 N1 and 52 N2 patients
in the study population. Because we se-
lected non-small cell lung cancer pa-
tients with nodal metastasis, those pa-
tients are homogenous in terms of nodal
metastasis in our opinion. We thought
that the T stage was not an important
factor because the purpose of this study
was comparing between the primary tu-
mor and the metastatic nodes, and the
survival in this group of patients is usu-
ally determined by nodal metastasis rather
than the status of the primary tumor. For
the same reason, the treatment method
(such as the extent of surgical resection)
would not be an important factor for the
difference in the protein expression lev-
els. We thought that the treatment in this
study was relatively homogenous in that
all the patients received complete surgi-
cal resection and platinum-based che-
motherapy.
Thanks again for your consider-
ation.
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Serum Concentrations
of Erlotinib at a Dose
of 25 mg Daily
To the Editor:
In this journal, our group recently
reported a retrospective review of the
clinical efficacy of erlotinib at a dose of
25 mg/d for patients with metastatic
non-small cell lung cancers (NSCLCs)
with somatic mutations in the epidermal
growth factor receptor (EGFR) gene.1
The seven patients included in that study
attained a response rate of 71.5% and a
median progression-free survival of 17
months (95% CI, 6–35 months). We
speculated that the serum concentrations
achieved with erlotinib 25 mg/d were
similar to the serum concentrations ob-
served with gefitinib 250 mg/d. Based
on the published phase I trials for these
EGFR tyrosine kinase inhibitors, the
mean serum trough concentration at-
tained with gefitinib 250 mg/d was be-
tween 0.16 and 0.24 g/mL or 0.35 and
0.53 M,2 whereas the mean serum con-
centration measured with erlotinib 25
mg/d was approximately 0.22 g/mL or
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